Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Colorectal Neoplasms 270Stomach Neoplasms 200Rectal Neoplasms 180Pancreatic Neoplasms 131Colonic Neoplasms 112Neoplasm Metastasis 74Esophageal Neoplasms 63Carcinoma, Hepatocellular 41Neoplasms 40Cholangiocarcinoma 36Adenocarcinoma Of Esophagus 32Adenocarcinoma 32Biliary Tract Neoplasms 25Liver Neoplasms 21Gallbladder Neoplasms 21Recurrence 18Gastrointestinal Neoplasms 18Lymphoma, Large B-Cell, Diffuse 17Peritoneal Neoplasms 16Carcinoma, Non-Small-Cell Lung 16Breast Neoplasms 16Esophageal Squamous Cell Carcinoma 14Locally Advanced Rectal Cancer 12Bile Duct Neoplasms 11Colorectal Cancer Metastatic 8Unspecified Adult Solid Tumor, Protocol Specific 7Ovarian Neoplasms 7Lymphoma, Extranodal NK-T-Cell 7Head and Neck Neoplasms 7Appendiceal Neoplasms 7

Interventions

irinotecan sucrosofate 1apatinib 1Temozolomide 1Tegafur 1S 1 (combination) 1Oxaliplatin 1Leucovorin 1Fluorouracil 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Efficacy and Safety × Oxaliplatin × Clear all
NCT06383078 2024-04-25

HR070803 in Combination With Oxaliplatin, S-1 Versus NALIRIFOX as Adjuvant Therapy for Pancreatic Cancer

The First Affiliated Hospital with Nanjing Medical University

Phase 2 Not yet recruiting
120 enrolled

Efficacy and Safety

Data powered by HemOnc (CC BY 4.0) Colophon âš¡